Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen.
Thomas MeyerAndré MaierZeljko UzelacTim HagenackerRene GüntherOlivia Schreiber-KatzMarkus WeilerRobert SteinbachUte WeyenJan Christoph KochDagmar KettemannJenny NordenJohannes DorstClaudia WursterAlbert C LudolphBenjamin StolteMaren FreigangAlma OsmanovicSusanne PetriJulian GrosskreutzAnnekathrin RödigerRamona GriepMarcel GaudlitzBertram WalterChristoph MünchSusanne SpittelPublished in: European journal of neurology (2021)
Nusinersen was administered across a broad range of ages, disease durations and motor function deficits. Treatment expectations were highly differentiated and related to SMA type and functional status. Patient-reported outcomes demonstrated a positive perception of nusinersen therapy in adult patients with 5q-SMA.